MX2022000744A - Extraccion de celulas tumorales a partir de recuperacion de sangre intraoperatoria autologa mediante un anticuerpo trifuncional. - Google Patents

Extraccion de celulas tumorales a partir de recuperacion de sangre intraoperatoria autologa mediante un anticuerpo trifuncional.

Info

Publication number
MX2022000744A
MX2022000744A MX2022000744A MX2022000744A MX2022000744A MX 2022000744 A MX2022000744 A MX 2022000744A MX 2022000744 A MX2022000744 A MX 2022000744A MX 2022000744 A MX2022000744 A MX 2022000744A MX 2022000744 A MX2022000744 A MX 2022000744A
Authority
MX
Mexico
Prior art keywords
removal
tumor cells
blood salvage
trifunctional antibody
autologous blood
Prior art date
Application number
MX2022000744A
Other languages
English (en)
Inventor
Horst Lindhofer
Original Assignee
Lindis Blood Care Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lindis Blood Care Gmbh filed Critical Lindis Blood Care Gmbh
Publication of MX2022000744A publication Critical patent/MX2022000744A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3687—Chemical treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3615—Cleaning blood contaminated by local chemotherapy of a body part temporarily isolated from the blood circuit
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3692—Washing or rinsing blood or blood constituents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/38—Removing constituents from donor blood and storing or returning remainder to body, e.g. for transfusion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/0021—Special media to be introduced, removed or treated removed from and reintroduced into the body, e.g. after treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A61M2202/0413—Blood

Landscapes

  • Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • External Artificial Organs (AREA)

Abstract

La invención se refiere a un método realizado ex vivo para la eliminación de células tumorales a partir de la recuperación de sangre recogida de manera intraoperatoria, en donde se usa un anticuerpo trifuncional para unirse a un leucocito, una célula tumoral y una célula positiva para el receptor Fc. La invención también se refiere al uso de dicho método ex vivo para la eliminación de células tumorales a partir de la recuperación de sangre extraída de manera intraoperatoria seguido de la reintroducción de la recuperación de sangre purificada obtenida de este modo o de concentrados de eritrocitos purificados por dicho método a un paciente del que se obtuvo dicha sangre recogida de manera intraoperatoria.
MX2022000744A 2019-07-18 2020-07-20 Extraccion de celulas tumorales a partir de recuperacion de sangre intraoperatoria autologa mediante un anticuerpo trifuncional. MX2022000744A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19186959 2019-07-18
PCT/EP2020/070459 WO2021009383A1 (en) 2019-07-18 2020-07-20 Removal of tumor cells from intraoperative autologous blood salvage by using a trifunctional antibody

Publications (1)

Publication Number Publication Date
MX2022000744A true MX2022000744A (es) 2022-04-18

Family

ID=67437964

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000744A MX2022000744A (es) 2019-07-18 2020-07-20 Extraccion de celulas tumorales a partir de recuperacion de sangre intraoperatoria autologa mediante un anticuerpo trifuncional.

Country Status (8)

Country Link
EP (1) EP3986500A1 (es)
JP (1) JP2022541551A (es)
KR (1) KR20220038396A (es)
CN (1) CN114364415A (es)
AU (1) AU2020313377A1 (es)
BR (1) BR112022000930A2 (es)
MX (1) MX2022000744A (es)
WO (1) WO2021009383A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122009000068I2 (de) 1994-06-03 2011-06-16 Ascenion Gmbh Verfahren zur Herstellung von heterologen bispezifischen Antikörpern
EP2578230A1 (en) * 2011-10-04 2013-04-10 Trion Pharma Gmbh Removal of Tumor Cells from Intraoperative Autologous Blood Salvage
RU2693264C2 (ru) * 2012-02-03 2019-07-01 Ф.Хоффман-Ля Рош Аг Молекулы биспецифических антител и т-клетки, трансфецированные антигеном, и их применение в медицине

Also Published As

Publication number Publication date
WO2021009383A1 (en) 2021-01-21
EP3986500A1 (en) 2022-04-27
KR20220038396A (ko) 2022-03-28
JP2022541551A (ja) 2022-09-26
AU2020313377A1 (en) 2022-02-03
BR112022000930A2 (pt) 2022-03-08
CN114364415A (zh) 2022-04-15

Similar Documents

Publication Publication Date Title
TR201906285T4 (tr) İntraoperatif otolog kan kurtarımından tümör hücrelerinin giderilmesi.
MX2021012669A (es) Proceso para sintetizar 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5- il)-piridin-3-il)metoxi)benzaldehido.
PH12015501558B1 (en) Human antibodies to respiratory syncytial virus f protein and methods of use thereof
Mendrone Jr et al. Factors affecting hematopoietic progenitor cell mobilization: an analysis of 307 patients
MX370137B (es) Sistema para purificar ciertas poblaciones celulares en sangre o medula osea por agotamiento.
BR112012024350A2 (pt) métodos para tratar paciente atraves da separação de ctcs, para capturar células de tumor circulantes (ctc) em fluido corporal e para descobrir fármacos, ctcs isoladas, filtro de captura de ctcs em fluido corporal e dispositivos extracorpóreos para a captura de ctcs em fluido corporal
MX2020010369A (es) Particulas implantables y metodos relacionados.
EA201590671A1 (ru) Комбинация антител к kir и антител к pd-1 для лечения злокачественной опухоли
EA201790025A1 (ru) Создание банка мезенхимальных стромальных клеток из объединенных мононуклеарных клеток нескольких доноров костного мозга
MX2017014812A (es) Metodos para el almacenamiento de sangre completa y composiciones de esta.
EA202090922A1 (ru) Композиции и способы истощения cd2+ клеток
EA201591522A1 (ru) Лечение реакции трансплантат против хозяина у подвергаемых трансплантации пациентов
MX2022000744A (es) Extraccion de celulas tumorales a partir de recuperacion de sangre intraoperatoria autologa mediante un anticuerpo trifuncional.
MX2019013614A (es) Seleccion y uso de fracciones de celulas del cordon umbilical adecuadas para trasplante.
MX2019013613A (es) Seleccion y uso de fracciones de celulas del cordon umbilical adecuadas para trasplante.
BR112022014333A2 (pt) Anticorpos multiespecíficos para uso no tratamento de doenças
Bachegowda et al. HLA-mismatched bone marrow transplantation in severe aplastic anemia
Saliba et al. Endothelial Activation and Stress Index (EASIX) is associated with fluid overload and survival in recipients of allogeneic stem cell transplantation
Snyder et al. The Stemex Phase II/III Study: challenges in production and delivery of centrally manufactured ex vivo expanded umbilical cord blood (UCB) CD133+ cells to patients with advanced hematological malignancies
Jamal et al. Use of Sysmex Hematology Analyzer based Hematopoietic Progenitor Cell (XN-HPC) Count in Allogeneic Peripheral Blood Stem Cell Transplant Setting; Is It Substantially Reliable?
EA202190616A1 (ru) Лиофилизат треосульфана
Dragon et al. Depletion of alloreactive B cells by chimeric alloantigen receptor T cells with drug resistance to prevent antibody-mediated rejection in solid organ transplantation
UA56636U (ru) Способ предоперационной подготовки больных фибромиомой матки
UA53882U (ru) Способ определения эндогенной интоксикации организма при нарушениях толстокишечного транзита
RU2013135071A (ru) Способ определения адгезивности клеток крови